Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Table 2 Relationship between anti-nucleosome antibody and other disease parameters among patients under study

Variable n (%) or mean ± SD		Positive Anti-nucleosome (n = 49)	Negative Anti-nucleosome (n = 31)	t/x²	P value
Clinical features	Arthritis	42 (85.7)	30 (96.8)	2.581	0.108
	Pleurisy	28 (57.1)	14 (45.2)	1.093	0.296
	Fever	27 (55.1)	12 (38.7)	2.042	0.153
	Malar rash	27 (55.1)	23 (74.2)	2.953	0.086
	Oral ulcers	24 (49.0)	14 (45.2)	0.111	0.739
	Alopecia	22 (44.9)	12 (38.7)	0.298	0.585
	Photosensitivity	15 (30.6)	16 (51.6)	3.528	0.060
	Neurologic manifestations	13 (26.5)	7 (22.6)	0.158	0.691
	APS	12 (24.5)	7 (22.6)	0.038	0.845
	Vasculitis	11 (22.4)	3 (9.7)	2.145	0.143
	Pericarditis	8 (16.3)	2 (6.5)	1.693	0.193
	Discoid rash	4 (8.2)	2 (6.5)	0.080	0.777
	Myositis	1 (2.0)	0 (0.0)	0.641	0.423
	Nephritis	24 (49%)	16 (51.6)	2.937	0.230
ECLAM		4.1 ± 2.2	3.3 ± 1.8	1.805	0.075
Laboratory features	ESR (mm/1st hour)	51.0 ± 30.7	43.7 ± 29.7	1.051	0.296
	Serum creatinine (μmol/L)	0.7 ± 0.3	1.0 ± 0.8	2.110	0.038
	Serum albumin (g/dl)	3.8 ± 0.7	4.0 ± 0.7	1.207	0.232
	Low C3 < 90 (mg/dl)	25 (51.0)	11 (35.5)	1.852	0.174
	Low C4 < 10 (mg/dl)	11 (22.4)	8 (25.8)	0.118	0.731

APS: Antiphospholipid syndrome, ESR: Erythrocyte sedimentation rate, ECLAM: European Consensus Lupus Activity Measurement

ISSN: 2523-3106